Cyclic blood flow variations induced by platelet-activating factor in stenosed canine coronary arteries despite inhibition of thromboxane synthetase, serotonin receptors, and alpha-adrenergic receptors.
Cyclic blood flow variations induced by platelet-activating factor in stenosed canine coronary arteries despite inhibition of thromboxane synthetase, serotonin receptors, and alpha-adrenergic receptors.
复制标题
尽管抑制了血栓素合成酶、5-羟色胺受体和α-肾上腺素能受体，但狭窄的犬冠状动脉中血小板激活因子仍会引起周期性血流变化。
DOI：
10.1161/01.cir.72.2.397
复制
发表时间：
1985
期刊：
影响因子：
37.8
通讯作者：
Willerson,JT
中科院分区：
文献类型：
--
作者：
Apprill,P;Schmitz,JM;Campbell,WB;Tilton,G;Ashton,J;Raheja,S;Buja,LM;Willerson,JT
磷脂血小板活化因子（PAF）刺激血小板聚集和冠状动脉血管收缩。在这项研究中，我们确定是否PAF改变冠状动脉血流模式在体内犬准备同心冠状动脉狭窄。该制剂的特征在于与冠状动脉狭窄部位的短暂血小板聚集相关的冠状动脉血流的周期性流动变化。在三个方案中使用了39只雄性杂种犬。在方案1中，将PAF（10（-9）或10（-8）mol/min）注入狭窄近端的冠状动脉，以确定（1）PAF是否引起循环血流变化和（2）PAF是否对全身血流动力学有影响。在6只犬中的3只中诱导了循环血流变化;在这些动物中，输注较低和较高剂量的PAF后10分钟，平均动脉压分别下降了5.5%和42.1%。在方案2中，使用血栓素合成酶抑制剂UK 38485（平均剂量2.2 mg/kg iv）、5-羟色胺拮抗剂酮色林（0.5 mg/kg iv）或α 2-肾上腺素能拮抗剂育亨宾（2 mg/kg iv）消除循环流量变化。随后给予PAF使循环血流变化频率恢复至拮抗剂前水平。血栓素（Tx）B2和6-酮-PGF 1 α，TxA 2和前列环素的稳定代谢产物，分别在冠状动脉狭窄远端获得的血液中进行测量。TxB 2水平大幅增加，在循环流量变化，并返回到控制值与血栓素合成酶抑制剂UK 38485。PAF的输注随后恢复了循环流量变化，而不改变冠状动脉冠状动脉TxB 2水平。（250字处删节）
The phospholipid platelet-activating factor (PAF) stimulates platelet aggregation and coronary vasoconstriction. In this study we determined whether PAF alters coronary flow patterns in vivo in a canine preparation with concentric coronary artery stenosis. This preparation is characterized by cyclic flow variations in coronary blood flow associated with transient platelet aggregation at the site of the coronary constriction. Thirty-nine male mongrel dogs were used in three protocols. In protocol 1, PAF (10(-9) or 10(-8) mol/min) was infused into the coronary artery proximal to the stenosis to determine (1) whether PAF induces cyclic flow variations and (2) whether PAF has an effect on systemic hemodynamics. Cyclic flow variations were induced in three of six dogs; in these animals, mean arterial pressure decreased by 5.5% and 42.1% 10 min after infusion of the lower and higher dose of PAF. In protocol 2, cyclic flow variations were abolished with either the thromboxane synthetase inhibitor UK38485 (mean dose 2.2 mg/kg iv), the serotonin antagonist ketanserin (0.5 mg/kg iv), or the alpha 2-adrenergic antagonist yohimbine (2 mg/kg iv). Subsequent administration of PAF restored the frequency of cyclic flow variations to the preantagonist levels. Thromboxane (Tx) B2 and 6-keto-PGF1 alpha, the stable metabolites of TxA2 and prostacyclin, respectively, were measured in blood obtained distal to the coronary stenosis. TxB2 levels increased substantially during cyclic flow variations and were returned to control values with the thromboxane synthetase inhibitor UK38485. Infusion of PAF subsequently restored cyclic flow variations without altering coronary arterial coronary arterial TxB2 levels.(ABSTRACT TRUNCATED AT 250 WORDS)